RESEARCH TRIANGLE PARK – Drug giant GlaxoSmithKline will close a facility in Memphis, affecting more than 150 workers.
The company disclosed the shutdown in a mass layoff notice with the state of Tennessee. The closure will take place in September 2022.
GSK is planning to split in two and is under pressure from activist investor Elliott Management Corp. The company plans to spin off its consumer products group.
“The London-based company invested $2 million in the plant in 2015 after reversing a decision to sell the factory, a producer of Polident and Corega denture-cleaning products and other over-the-counter products sold by GlaxoSmithKline,” the newspaper Commercial Appeal noted.
GSK maintains a significant presence in RTP and operates a manufacturing plant in Zebulon.
The firm manufactures solid-dose products, including tablets and capsules, at its Zebulon facility. The plant also does granulation, drying and packaging, and contract manufacturing of antibiotics for other companies, according to the N.C. Biotech Center.
GSK board backs CEO Walmsley in dispute: She is ‘the right leader of New GSK’
